# Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen

> **NCT01037348** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 65 (actual)

## Conditions studied

- Choroidal Neovascularisation

## Interventions

- **DRUG:** ranibizumab 0.5mg

## Key facts

- **NCT ID:** NCT01037348
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2016-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01037348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01037348, "Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01037348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*